Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-35274
Titel: Shotgun lipidomics of liver and brain tissue of Alzheimer's disease model mice treated with acitretin
VerfasserIn: Lauer, Anna A.
Janitschke, Daniel
Dos Santos Guilherme, Malena
Nguyen, Vu Thu Thuy
Bachmann, Cornel M.
Qiao, Sen
Schrul, Bianca
Boehm, Ulrich
Grimm, Heike S.
Hartmann, Tobias
Endres, Kristina
Grimm, Marcus O. W.
Sprache: Englisch
Titel: Scientific Reports
Bandnummer: 11
Heft: 1
Verlag/Plattform: Springer Nature
Erscheinungsjahr: 2021
Freie Schlagwörter: Alzheimer's disease
Lipidomics
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Alzheimer’s disease (AD) is a very frequent neurodegenerative disorder characterized by an accumulation of amyloid-β (Aβ). Acitretin, a retinoid-derivative and approved treatment for Psoriasis vulgaris, increases non-amyloidogenic Amyloid-Precursor-Protein-(APP)-processing, prevents Aβ-production and elicits cognitive improvement in AD mouse models. As an unintended side effect, acitretin could result in hyperlipidemia. Here, we analyzed the impact of acitretin on the lipidome in brain and liver tissue in the 5xFAD mouse-model. In line with literature, triglycerides were increased in liver accompanied by increased PCaa, plasmalogens and acyl-carnitines, whereas SM-species were decreased. In brain, these effects were partially enhanced or similar but also inverted. While for SM and plasmalogens similar effects were found, PCaa, TAG and acyl-carnitines showed an inverse effect in both tissues. Our findings emphasize, that potential pharmaceuticals to treat AD should be carefully monitored with respect to lipid-homeostasis because APP-processing itself modulates lipid-metabolism and medication might result in further and unexpected changes. Moreover, deducing effects of brain lipid-homeostasis from results obtained for other tissues should be considered cautiously. With respect to acitretin, the increase in brain plasmalogens might display a further positive probability in AD-treatment, while other results, such as decreased SM, indicate the need of medical surveillance for treated patients.
DOI der Erstveröffentlichung: 10.1038/s41598-021-94706-3
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-352748
hdl:20.500.11880/32191
http://dx.doi.org/10.22028/D291-35274
ISSN: 2045-2322
Datum des Eintrags: 17-Jan-2022
Bezeichnung des in Beziehung stehenden Objekts: Supplementary Information
In Beziehung stehendes Objekt: https://static-content.springer.com/esm/art%3A10.1038%2Fs41598-021-94706-3/MediaObjects/41598_2021_94706_MOESM1_ESM.xlsx
https://static-content.springer.com/esm/art%3A10.1038%2Fs41598-021-94706-3/MediaObjects/41598_2021_94706_MOESM2_ESM.pdf
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Experimentelle und Klinische Pharmakologie und Toxikologie
M - Medizinische Biochemie und Molekularbiologie
M - Neurologie und Psychiatrie
Professur: M - Prof. Dr. Ulrich Boehm
M - Prof. Dr. Tobias Hartmann
M - Jun.-Prof. Dr. Bianca Schrul
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Dateien zu diesem Datensatz:
Datei Beschreibung GrößeFormat 
s41598-021-94706-3.pdf2,69 MBAdobe PDFÖffnen/Anzeigen


Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons Creative Commons